

IN THE CLAIMS

Please amend claims 1-5 and 28-32 as follows:

1. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier.
2. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 85% or more by weight of the total weight of tofisopam.
3. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 90% or more by weight of the total weight of tofisopam.
4. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 95% or more by weight of the total weight of tofisopam.

10/21/  
2004  
1:21  
PM

5. (Amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 99% or more by weight of the total weight of tofisopam.
28. (Amended) The pharmaceutical composition according to claim 1, wherein the composition is for intraperitoneal, subcutaneous, intranasal, intramuscular, intrathecal, sublingual, rectal, intravenous infusion, transdermal delivery or oral administration.